Abstract: Compositions and methods for improving nitric oxide levels in a subject, comprising administering to a subject, a composition comprising dietary nitrate derived from potassium nitrate, beet root (whole plant, powder, plant extract), and/or nitrate-rich leafy green portions (whole plant, powder, plant extract) that improve functional nitric oxide levels in subjects as shown by increasing salivary bioconversion of nitrate to nitrite, a necessary a required step for nitric oxide mediated health benefits. The disclosed novel compositions improve cardiac health, lowers blood pressure, intraocular pressure, and LDL and restores nitric oxide mediated cardiovascular benefits, including but not limited, restoring endothelium function and improving flow mediated dilation.
Abstract: The present disclosure relates to a hair styling compositions that exhibit non-Newtonian shear thickening behavior. The hair styling composition include: (a) about 0.1 to about 7 wt. % of AMP-acrylates/allyl methacrylate copolymer, based on the total weight of the hair styling composition; (b) one or more nonionic film-forming polymers; (c) one or more polysaccharides; (d) one or more nonionic surfactants; and (e) water. Additional components such as, for example, water-soluble solvents, fatty compounds, amphoteric film-forming polymers, volatile or non-volatile silicones, thickeners (ionic or non-ionic), etc., may also optionally be included. The hair styling compositions are particularly useful for styling or shaping hair and for providing hold, discipline, and texture to hair.
Type:
Grant
Filed:
November 15, 2019
Date of Patent:
October 25, 2022
Assignee:
L'OREAL
Inventors:
Azizah Khader Suleiman, Anand Ramachandra Mahadeshwar, Anna Leticia M. Botto, Emma Jean Naiberk, Vanessa Decarlo
Abstract: A planning device generating control data for a treatment apparatus for refraction-correcting ophthalmic surgery is provided, said apparatus using a laser device to separate a corneal volume, which is to be removed for correction, from the surrounding cornea by at least one cut surface in the cornea of an eye, said planning device comprising an interface for receiving corneal data including information on pre-operative cuts which were generated in a previous ophthalmic operation, and computing means for defining a corneal cut surface which confines the corneal volume to be removed, said computing means defining the corneal cut surface on the basis of the corneal data and generating a control dataset for the corneal cut surface for control of the laser device.
Type:
Grant
Filed:
March 23, 2020
Date of Patent:
October 18, 2022
Assignee:
Carl Zeiss Meditec AG
Inventors:
Mark Bischoff, Dirk Muehlhoff, Gregor Stobrawa
Abstract: Aspects of the disclosure relate methods and a synthetic cell delivery device for treating trauma present relative to the inner surface of a hollow organ such as an esophagus.
Abstract: Methods and monodisperse glass microsphere composites comprising a porous wall hollow-glass microsphere; a cargo of a therapeutic is loaded inside of the porous wall hollow-glass microsphere; and a first shell fully encapsulating the porous wall hollow-glass microsphere and capping pores in the walls, retaining the cargo inside of the porous wall hollow-glass microsphere.
Type:
Grant
Filed:
April 29, 2020
Date of Patent:
October 11, 2022
Assignees:
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, APPLIED RESEARCH CENTER, INC.
Inventors:
Paul M. Weinberger, George Wicks, William D. Hill
Abstract: Systems featuring two or more encapsulation devices stacked together. The encapsulation devices house cells, such as but not limited to islet cells or stem cell derived beta cells or the like. e.g., for regulating blood glucose, or other cells or spheroids that can produce and release a therapeutic agent that is useful in the body, etc. The system may feature oxygen delivery, or in some cases no exogenous oxygen is delivered and vascularization of the device can help provide oxygen and other needed nutrient to the cells. The system of the present invention may be used in conjunction with other therapies such as an artificial pancreas. Stacking the devices with blood vessel formation around and in between them may allow for a decrease in the footprint that would be needed for implantation.
Type:
Grant
Filed:
November 3, 2017
Date of Patent:
September 20, 2022
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Abstract: The subject of the present invention is cosmetic or pharmaceutical compositions which are protective against common skin irritants or allergens. The invention is also directed to the use of these compositions to protect skin from the effects of metal. Another object of the invention is a method of preventing or protecting the skin from the effects of metal, using the compositions of the invention.
Type:
Grant
Filed:
August 5, 2014
Date of Patent:
September 13, 2022
Assignee:
AMANTIN EXPERTS
Inventors:
Elisabeth Briand, Jean-Baptiste Dumas Milne Edwards, Jacques Delort
Abstract: This invention relates to kits including novel oral food challenge meal formulations. In particular, the invention also relates to kits including novel oral food challenge meal formulations, wherein the placebo dose formulation is indistinguishable from non-placebo dose formulations.
Type:
Grant
Filed:
December 5, 2016
Date of Patent:
September 13, 2022
Assignee:
Reacta Biotech Limited
Inventors:
Clare Mills, Anuradha Balasundaram, Carol Ann Costello, Ivona Baricevic-Jones, Martin Wickham
Abstract: An oral solid non-pulsatile 24 hours prolonged-release composition including an amount of betahistine, or of a pharmaceutically acceptable salt thereof, equivalent to 48 mg of betahistine dihydrochloride, together with one or more pharmaceutically acceptable excipients or carriers, wherein the composition exhibits a dissolution profile according to which: up to 30% by weight of betahistine is dissolved in 1 hour; from 35% to 45% by weight of betahistine is dissolved in 2 hours; from 46% to 60% by weight of betahistine is dissolved in 4 hours; from 61% to 80% by weight of betahistine is dissolved in 8 hours; from 81% to 97% by weight of betahistine is dissolved in 16 hours; and from 98% to 100% by weight of betahistine is dissolved in 24 hours. It also relates to the treatment of a vestibular disease or condition, more particularly in the treatment of Ménière's disease.
Abstract: Biomaterials, implants made therefrom, methods of making the biomaterial and implants, methods of promoting bone or wound healing in a mammal by administering the biomaterial or implant to the mammal, and kits that include such biomaterials, implants, or components thereof. The biomaterials may be designed to exhibit osteogenic, osteoinductive, osteoconductive, and/or osteostimulative properties.
Type:
Grant
Filed:
July 28, 2015
Date of Patent:
August 30, 2022
Assignee:
Globus Medical, Inc.
Inventors:
Jennifer Klimek, Archana Bhat, Vipin Kunjachan, Chris Geisler, Allison Adams, Christine Grimes
Abstract: A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.
Abstract: The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.
Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
August 30, 2022
Assignee:
Saniona A/S
Inventors:
Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
Abstract: Therapeutic or prophylactic compositions providing an active agent, such as an antigen or a vector that contains and expresses an antigen, encapsulated in or incorporated into a biodegradable polymeric particle are provided. The compositions can also provide an active agent that is not encapsulated in or incorporated into the biodegradable polymeric particle in order to provide an initial or prime delivery of the active agent. Particles or composites providing an active agent encapsulated by a first and second polymer are also provided, wherein polymers are distributed in a gradient from a core of the composite to a surface of the composite, and configured to provide a delayed release of the active agent by a period of 7 days to 6 months. Methods of producing composites are also provided.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
July 26, 2022
Assignees:
Auburn University, Altimmune, Inc.
Inventors:
Allan E. David, Henry J. Baker, Aime K. Johnson, M. Scot Roberts, Kent R. Van Kampen, Prachi Sangle
Abstract: This invention relates to kits including novel oral food challenge meal formulations. In particular, the invention also relates to kits including novel oral food challenge meal formulations, wherein the placebo dose formulation is indistinguishable from non-placebo dose formulations.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
July 19, 2022
Assignee:
Reacta Biotech Limited
Inventors:
Clare Mills, Anuradha Balasundaram, Carol Ann Costello, Ivona Baricevic-Jones
Abstract: The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
July 19, 2022
Assignee:
Proterris Inc.
Inventors:
Jeffrey D. Wager, Joseph Wager, Alex Stenzler, David Pinsky, Augustine Choi
Abstract: Disclosed are pharmaceutical compositions having a portion of ketamine for intraoral release and another ketamine for gastrointestinal release. The compositions can further include aspirin. The disclosed formulations and related administration approaches improve the bioavailability and efficacy of oral ketamine.
Abstract: This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using zinc or a zinc chelator to treat rotator cuff conditions are provided.
Type:
Grant
Filed:
March 18, 2020
Date of Patent:
July 5, 2022
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Scott M. Riester, John W. Sperling, Andre J. van Wijnen
Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.
Type:
Grant
Filed:
July 10, 2018
Date of Patent:
July 5, 2022
Assignee:
Eli Lilly and Company
Inventors:
Matthew Carl Allgeier, Tony Yantao Zhang
Abstract: Compositions that are suitable for use as a disinfectant are disclosed. Methods of making and using compositions that are suitable for use as a disinfectant are also disclosed.